In This Article:
- By insider
President & CEO of Sarepta Therapeutics Inc (SRPT) Douglas S Ingram bought 16,695 shares of SRPT on 10/30/2018 at an average price of $120.39 a share. The total cost of this purchase was $2 million.
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases. Sarepta Therapeutics Inc has a market cap of $8.3 billion; its shares were traded at around $124.43 with and P/S ratio of 33.02. Sarepta Therapeutics Inc had annual average EBITDA growth of 2.70% over the past five years.
-
Warning! GuruFocus has detected 5 Warning Signs with SRPT. Click here to check it out.
-
The intrinsic value of SRPT
CEO Recent Trades:
-
President & CEO Douglas S Ingram bought 16,695 shares of SRPT stock on 10/30/2018 at the average price of $120.39. The price of the stock has increased by 3.36% since.
CFO Recent Trades:
-
EVP, CFO & CBO Sandesh Mahatme sold 107,524 shares of SRPT stock on 10/24/2018 at the average price of $127.74. The price of the stock has decreased by 2.59% since.
For the complete insider trading history of SRPT, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 5 Warning Signs with SRPT. Click here to check it out.
-
The intrinsic value of SRPT